688176 亚虹医药
已收盘 02-10 15:00:01
资讯
新帖
简况
股市必读：亚虹医药（688176）预计2025年全年营业收入2.42亿元至2.91亿元
证券之星 · 02-02
股市必读：亚虹医药（688176）预计2025年全年营业收入2.42亿元至2.91亿元
亚虹医药（688176）披露2025年年度业绩预亏公告，1月30日股价下跌3.27%
证券之星 · 01-30
亚虹医药（688176）披露2025年年度业绩预亏公告，1月30日股价下跌3.27%
1月29日亚虹医药跌7.91%，中航优选领航混合发起A基金重仓该股
证券之星 · 01-29
1月29日亚虹医药跌7.91%，中航优选领航混合发起A基金重仓该股
每周股票复盘：亚虹医药（688176）PL-2501预计2026年中报IND
证券之星 · 01-25
每周股票复盘：亚虹医药（688176）PL-2501预计2026年中报IND
亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可
智通财经 · 01-22
亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可
【机构调研记录】建信基金调研爱迪特、亚虹医药
证券之星 · 01-22
【机构调研记录】建信基金调研爱迪特、亚虹医药
每周股票复盘：亚虹医药（688176）拟用不超12亿闲置募资做现金管理
证券之星 · 01-18
每周股票复盘：亚虹医药（688176）拟用不超12亿闲置募资做现金管理
亚虹医药（688176）披露使用部分暂时闲置募集资金进行现金管理，1月16日股价上涨1.75%
证券之星 · 01-16
亚虹医药（688176）披露使用部分暂时闲置募集资金进行现金管理，1月16日股价上涨1.75%
每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组
证券之星 · 01-11
每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组
亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%
证券之星 · 01-08
亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%
亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组
智通财经 · 01-08
亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组
每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效
证券之星 · 01-02
每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效
股市必读：亚虹医药（688176）12月29日披露最新机构调研信息
证券之星 · 2025-12-30
股市必读：亚虹医药（688176）12月29日披露最新机构调研信息
每周股票复盘：亚虹医药（688176）APLD-2304获欧洲注册受理
证券之星 · 2025-12-28
每周股票复盘：亚虹医药（688176）APLD-2304获欧洲注册受理
亚虹医药：陈宝华正式履职董事会秘书
证券之星 · 2025-12-21
亚虹医药：陈宝华正式履职董事会秘书
亚虹医药：APLD-2304申报欧洲医疗器械注册获接收
证券之星 · 2025-12-21
亚虹医药：APLD-2304申报欧洲医疗器械注册获接收
亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准
智通财经 · 2025-12-17
亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准
亚虹医药：安信基金、中信建投基金等多家机构于12月12日调研我司
证券之星 · 2025-12-12
亚虹医药：安信基金、中信建投基金等多家机构于12月12日调研我司
【机构调研记录】淳厚基金调研亚虹医药
证券之星 · 2025-12-12
【机构调研记录】淳厚基金调研亚虹医药
亚虹医药：有知名机构希瓦资产参与的多家机构于12月9日调研我司
证券之星 · 2025-12-11
亚虹医药：有知名机构希瓦资产参与的多家机构于12月9日调研我司
加载更多
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是APL-1702、海克威、APL-1202/APL-1501、APL-2302、APL-2501、APL-2304、APL-1401、APL-2301、马来酸奈拉替尼片（商品名：欧优比）、培唑帕尼片（商品名：迪派特）、甲磺酸艾立布林注射液（商品名：欧纳琳）。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":12.13,"timestamp":1770706801000,"preClose":12.26,"halted":0,"volume":4750746,"delay":0,"changeRate":-0.0106,"floatShares":436000000,"shares":571000000,"eps":-0.6341,"marketStatus":"已收盘","change":-0.13,"latestTime":"02-10 15:00:01","open":12.33,"high":12.33,"low":12.11,"amount":57822500,"amplitude":0.0179,"askPrice":12.14,"askSize":10,"bidPrice":12.13,"bidSize":1870,"shortable":0,"etf":0,"ttmEps":-0.6341,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.26,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770687000000,1770694200000],[1770699600000,1770706800000]],"highLimit":13.49,"lowLimit":11.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":571170486,"isCdr":false,"pbRate":3.97,"roa":"--","roe":"--","epsLYR":-0.68,"committee":0.498656,"marketValue":6928000000,"turnoverRate":0.0109,"status":1,"afterMarket":{"amount":0,"volume":0,"close":12.13,"buyVolume":0,"sellVolume":0,"time":1770708837558,"indexStatus":"已收盘 02-10 15:30:00","preClose":12.26},"floatMarketCap":5285000000},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2608326885","title":"股市必读：亚虹医药（688176）预计2025年全年营业收入2.42亿元至2.91亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608326885","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608326885?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:09","pubTimestamp":1769965751,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，亚虹医药报收于12.72元，下跌3.27%，换手率4.31%，成交量18.76万手，成交额2.41亿元。来自公司公告汇总：亚虹医药预计2025年度归属净利润亏损3.78亿元至4.53亿元，较上年同期亏损同比增加18.00%到减少1.67%。业绩披露要点业绩预告亚虹医药发布业绩预告，预计2025年全年营业收入2.42亿元至2.91亿元；扣非后净利润亏损3.96亿元至4.76亿元；归属净利润亏损3.78亿元至4.53亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176"],"gpt_icon":0},{"id":"2607704941","title":"亚虹医药（688176）披露2025年年度业绩预亏公告，1月30日股价下跌3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704941","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704941?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:15","pubTimestamp":1769782551,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，亚虹医药报收于12.72元，较前一交易日下跌3.27%，最新总市值为72.65亿元。该股当日开盘13.15元，最高13.35元，最低12.48元，成交额达2.41亿元，换手率为4.31%。近日，江苏亚虹医药科技股份有限公司发布2025年年度业绩预亏公告。2025年度营业收入预计为24,248.13万元到29,097.76万元，同比增长20.30%到44.36%；研发费用预计为25,366.63万元到30,439.95万元，同比减少2.41%到18.67%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2607704576","title":"1月29日亚虹医药跌7.91%，中航优选领航混合发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704576","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704576?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:38","pubTimestamp":1769675900,"startTime":"0","endTime":"0","summary":"证券之星消息，1月29日亚虹医药跌7.91%，收盘报13.15元，换手率6.32%，成交量27.52万手，成交额3.74亿元。重仓亚虹医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为中航基金的中航优选领航混合发起A。中航优选领航混合发起A目前规模为0.47亿元，最新净值1.7236，较上一交易日下跌0.35%，近一年上涨70.6%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900027043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2606232644","title":"每周股票复盘：亚虹医药（688176）PL-2501预计2026年中报IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232644","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232644?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:37","pubTimestamp":1769279829,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，亚虹医药报收于14.21元，较上周的13.39元上涨6.12%。本周，亚虹医药1月22日盘中最高价报14.54元，股价触及近一年最高点。本周关注点来自机构调研要点：PL-2501预计在2026年中期递交IND。来自公司公告汇总：APL-2401获澳大利亚Ⅰ期临床试验许可。PL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验已完成首例受试者入组。目前已完成人源化实验、体内外药效研究及前期安全性验证，预计2026年中期递交IND。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2605461931","title":"亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2605461931","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605461931?lang=zh_cn&edition=full","pubTime":"2026-01-22 17:27","pubTimestamp":1769074044,"startTime":"0","endTime":"0","summary":"按照澳大利亚药品注册相关法律法规，公司已获得该产品I期临床试验许可。此前APL-2401临床试验申请已获得国家药品监督管理局批准，公司将积极推进该产品的国际多中心临床研究。临床前实验表明APL-2401在多种FGFR2/3基因突变，扩增或过表达模型中展现出优异的疗效和更宽的安全窗。与现有同类产品相比，APL-2401在活性、选择性、安全性和成药性方面均显示出潜在的同类最佳优势，有望成为FGFR2/3靶向治疗领域的重磅产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚虹医药(688176.SH)：APL-2401在澳大利亚获得开展Ⅰ期临床试验许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2605117434","title":"【机构调研记录】建信基金调研爱迪特、亚虹医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2605117434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605117434?lang=zh_cn&edition=full","pubTime":"2026-01-22 08:12","pubTimestamp":1769040747,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及1月21日披露的机构调研信息，建信基金近期对2家上市公司进行了调研，相关名单如下：1）爱迪特 调研纪要：公司2025年上半年海外市场实现收入3.27亿元，同比增长34%，主要得益于大客户战略推进、全球化运营体系完善、产品线拓展及品牌建设。公司通过研发创新、生产降本和供应链协同提升毛利率。旗下最近一年表现最佳的公募基金产品为建信电子行业股票A，最新单位净值为2.18，近一年增长72.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200005640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0251","301580","BK0239"],"gpt_icon":0},{"id":"2604895925","title":"每周股票复盘：亚虹医药（688176）拟用不超12亿闲置募资做现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604895925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604895925?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:37","pubTimestamp":1768678627,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，亚虹医药报收于13.39元，较上周的11.99元上涨11.68%。本周，亚虹医药1月15日盘中最高价报13.57元，股价触及近一年最高点。本周关注点公司公告汇总：亚虹医药拟使用最高不超过12亿元闲置募集资金进行现金管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2603944469","title":"亚虹医药（688176）披露使用部分暂时闲置募集资金进行现金管理，1月16日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603944469","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603944469?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:39","pubTimestamp":1768574352,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，亚虹医药报收于13.39元，较前一交易日上涨1.75%，最新总市值为76.48亿元。该股当日开盘13.03元，最高13.54元，最低13.03元，成交额达2.51亿元，换手率为4.33%。亚虹医药近日发布公告称，公司于2026年1月16日召开董事会，审议通过了关于使用部分暂时闲置募集资金进行现金管理的议案。该事项已获董事会批准，保荐人无异议，无需提交股东大会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2602398635","title":"每周股票复盘：亚虹医药（688176）APL-2401完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2602398635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602398635?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:28","pubTimestamp":1768076889,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，亚虹医药报收于11.99元，较上周的11.51元上涨4.17%。本周，亚虹医药1月9日盘中最高价报12.24元。亚虹医药当前最新总市值68.48亿元，在化学制药板块市值排名85/150，在两市A股市值排名2758/5182。公司公告汇总江苏亚虹医药科技股份有限公司自愿披露关于APL-2401完成I期临床试验首例受试者入组公告。该药物已纳入国家药监局“30日通道”，并在获批后15个工作日内实现首例给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2601845398","title":"亚虹医药（688176）披露APL-2401完成I期临床试验首例受试者入组，1月8日股价上涨1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601845398","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601845398?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:24","pubTimestamp":1767882261,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，亚虹医药报收于11.78元，较前一交易日上涨1.55%，最新总市值为67.28亿元。该股当日开盘11.6元，最高11.91元，最低11.52元，成交额达1.42亿元，换手率为2.77%。公司近日发布公告称，其自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验已完成首例受试者入组。APL-2401为高选择性FGFR2/3双靶点小分子抑制剂，临床前研究显示其在多种FGFR2/3异常模型中具有优异疗效和更宽安全窗。目前该事项对公司近期业绩无重大影响，后续进展存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2601594773","title":"亚虹医药(688176.SH)：APL-2401完成I期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2601594773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601594773?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:09","pubTimestamp":1767859754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，公司自主研发的APL-2401在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验完成首例受试者入组。APL-2401是公司自主研发的高选择性成纤维生长因子受体2/3(FGFR2/3)双靶点小分子抑制剂，有望为晚期实体瘤(例如：尿路上皮癌、胆管癌、子宫内膜癌、胃癌、乳腺癌、卵巢癌、非小细胞肺癌和其他特定实体瘤)患者提供一种新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2600003991","title":"每周股票复盘：亚虹医药（688176）PL-1401在UC治疗中4周内显疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2600003991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600003991?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:11","pubTimestamp":1767298269,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，亚虹医药报收于11.06元，较上周的11.36元下跌2.64%。本周，亚虹医药12月22日盘中最高价报11.62元。PL-2401为全球同步研发的1类创新药，已纳入国家药监局“30日通道”，仅用22个工作日获得临床试验批准，系全国首批获批项目之一。相比现有产品，PL-2401显著降低FGFR1和FGFR4相关毒副作用，临床前模型中展现宽安全窗和优异疗效，具潜在同类最佳优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2595349577","title":"股市必读：亚虹医药（688176）12月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2595349577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595349577?lang=zh_cn&edition=full","pubTime":"2025-12-30 01:00","pubTimestamp":1767027645,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，亚虹医药报收于11.57元，上涨4.61%，换手率3.67%，成交量15.98万手，成交额1.83亿元。来自机构调研要点：PL-2401成为全国首批通过“30日通道”获批的创新药项目之一，仅用22个工作日获临床试验批准。PL-2401为全球同步研发的1类创新药，已获国家药监局批准开展在FGFR2/3驱动的晚期实体瘤患者中的I期临床试验，仅用22个工作日完成审批，成为全国首批纳入“30日通道”的项目之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000000567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2594478222","title":"每周股票复盘：亚虹医药（688176）APLD-2304获欧洲注册受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2594478222","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594478222?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:44","pubTimestamp":1766868248,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，亚虹医药报收于11.06元，较上周的11.36元下跌2.64%。本周，亚虹医药12月22日盘中最高价报11.62元。本周关注点公司公告汇总：APLD-2304向欧盟提交CE医疗器械注册申请并获接收。目前尚需通过欧盟公告机构审评审批方可上市销售。陈宝华先生自取得证明之日起正式履行董事会秘书职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2593129954","title":"亚虹医药：陈宝华正式履职董事会秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593129954","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593129954?lang=zh_cn&edition=full","pubTime":"2025-12-21 16:20","pubTimestamp":1766305242,"startTime":"0","endTime":"0","summary":"亚虹医药(688176.SH)公告称，近日，陈宝华参加了上海证券交易所科创板上市公司董事会秘书任职培训，并已取得了董事会秘书任职培训证明。公司已按相关规定将陈宝华的董事会秘书任职资格提交上海证券交易所备案。陈宝华自取得科创板上市公司董事会秘书任职培训证明之日起正式履行公司董事会秘书职责。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122100002839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2593260651","title":"亚虹医药：APLD-2304申报欧洲医疗器械注册获接收","url":"https://stock-news.laohu8.com/highlight/detail?id=2593260651","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593260651?lang=zh_cn&edition=full","pubTime":"2025-12-21 15:51","pubTimestamp":1766303467,"startTime":"0","endTime":"0","summary":"亚虹医药(688176.SH)公告称，公司产品APLD-2304向欧盟公告机构提交了医疗器械注册申请材料，并获得欧盟公告机构接收，后续尚需通过欧盟公告机构的审评、审批后方可上市销售。APLD-2304 是公司针对膀胱癌诊断及随访监测的使用场景和需求，研发的世界上首款便携式一次性蓝光膀胱软镜。由于产品的研发周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，对公司近期业绩不会产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122100001531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0239","688176","BK1222","BK1574","09996","09997","159883","BK1100"],"gpt_icon":0},{"id":"2592962161","title":"亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592962161","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592962161?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:42","pubTimestamp":1765957364,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)公告，公司收到国家药品监督管理局(NMPA)签发的《药物临床试验批准通知书》，公司APL-2401(药物名称为ASN-8639片)在FGFR2/3驱动的晚期实体瘤患者中开展I期临床试验申请获得批准。公告显示，APL-2401为全球同步研发的1类创新药，其国际多中心临床试验设计及申报资料符合国际临床试验技术标准体系要求，成功纳入国家药监局于2025年9月12日发布的《关于优化创新药临床试验审评审批有关事项的公告(2025年第86号)》规定的“30日通道”，并以仅22个工作日获得批准，成为全国首批获得此项新政审批通过的项目之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚虹医药(688176.SH)：APL-2401 临床试验申请获国家药品监督管理局批准","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2590650895","title":"亚虹医药：安信基金、中信建投基金等多家机构于12月12日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2590650895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590650895?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:01","pubTimestamp":1765537295,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月12日亚虹医药发布公告称安信基金、中信建投基金、西南证券、信达证券于2025年12月12日调研我司。PL-1401是公司通过自主研究并发现其全新作用机制用于治疗自身免疫疾病的口服创新药物。UC的炎症性质可导致持续性肠损伤，并增加住院、手术和结直肠癌的风险。PL-2302的临床前研究结果入选2024年美国癌症研究协会年会，并以壁报形式公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200031225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","601066","BK0239","688176"],"gpt_icon":0},{"id":"2590540501","title":"【机构调研记录】淳厚基金调研亚虹医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2590540501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590540501?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:11","pubTimestamp":1765498290,"startTime":"0","endTime":"0","summary":"淳厚基金成立于2018年，截至目前，资产管理规模199.12亿元，排名125/211；资产管理规模199.11亿元，排名107/211；管理公募基金数33只，排名122/211；旗下公募基金经理10人，排名107/211。旗下最近一年表现最佳的公募基金产品为淳厚信睿混合A，最新单位净值为3.46，近一年增长67.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200004442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2590916735","title":"亚虹医药：有知名机构希瓦资产参与的多家机构于12月9日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2590916735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590916735?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:44","pubTimestamp":1765446286,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月11日亚虹医药发布公告称国信证券资管、中银资管、信达证券、长盛基金、神农投资、希瓦资产、太保资产、申万宏源、从容投资、东吴基金、财通基金、诗佑私募基金、东方红基金、兴全基金、淳厚基金、信达澳银基金于2025年12月9日调研我司。目前公司正在全力加快推进其上市审评审批工作，以期尽快获得上市批准。PL-2302的临床前研究结果入选2024年美国癌症研究协会年会，并以壁报形式公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100028554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770724238923,"stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0225},{"period":"3month","weight":0.2447},{"period":"6month","weight":0.0049},{"period":"1year","weight":0.7243},{"period":"ytd","weight":0.0652}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25192人(较上一季度减少1.06%)","perCapita":"17294股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57117万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域医药的研发、生产和销售。公司的主要产品是APL-1702、海克威、APL-1202/APL-1501、APL-2302、APL-2501、APL-2304、APL-1401、APL-2301、马来酸奈拉替尼片（商品名：欧优比）、培唑帕尼片（商品名：迪派特）、甲磺酸艾立布林注射液（商品名：欧纳琳）。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}